论文部分内容阅读
目的 :探讨糖类抗原CA199及CA50 联合检测对胰腺癌诊断的临床价值及预后分析。方法 :用放射免疫分析法检测 30例健康者 ,2 0例慢性胰腺炎及 40例胰腺癌术前患者血清中CA199及CA50 的含量。结果 :胰腺癌患者术前血清CA199及CA50 值均明显高于正常组及慢性胰腺炎组 ,两者比较有显著性差异 (P <0 .0 1) ,CA199及CA50 两者联合检测较单测任何一项其灵敏度、特异性及准确性均有提高。胰腺癌伴有淋巴结转移的患者血清CA199及CA50 值较淋巴结无转移者亦增高 (P <0 .0 5 ) ,其阳性率亦高于无淋巴结转移者。结论 :CA199及CA50 联合检测可提高胰腺癌诊断的灵敏度、特异性及准确性 ,胰腺癌患者血清CA199及CA50 含量变化有助于预测胰腺癌有无转移及复发 ,是进行疗效观察的参考指标
Objective: To investigate the clinical value and prognosis of pancreatic cancer diagnosis with the combined detection of carbohydrate antigen CA199 and CA50. Methods: The serum CA199 and CA50 levels in 30 healthy subjects, 20 chronic pancreatitis patients and 40 pancreatic cancer patients before surgery were detected by radioimmunoassay. Results: Preoperative serum CA199 and CA50 values were significantly higher in patients with pancreatic cancer than in the normal group and chronic pancreatitis group. There was a significant difference between the two groups (P < 0.01). Joint detection of CA199 and CA50 was more common than single measurement. Any one has improved sensitivity, specificity, and accuracy. The serum CA199 and CA50 values of pancreatic cancer patients with lymph node metastasis were also higher than those without lymph node metastasis (P < 0.05), and the positive rate was higher than those without lymph node metastasis. Conclusion: The combined detection of CA199 and CA50 can improve the sensitivity, specificity and accuracy of the diagnosis of pancreatic cancer. The changes of serum CA199 and CA50 levels in pancreatic cancer patients can help predict the metastasis and recurrence of pancreatic cancer. It is a reference index for observation of curative effect.